An unusual case of heart attack-Reference-Cited by-同舟云学术

An unusual case of heart attack

Published:2018-05-23 Issue:1 Volume:18 Page:7-13
ISSN:2415-153X
Container-title:Hong Kong Bulletin on Rheumatic Diseases
language:en
Short-container-title:

Author:

Young Joyce Kit-Yu¹,Ng Daniel Kam Hung¹

Affiliation:

1. Department of Medicine and Geriatrics , Caritas Medical Centre , 111 Wing Hong Street, Sham Shui Po , Kowloon , Hong Kong

Abstract

Abstract We reported a patient with antiphospholipid syndrome (APS) secondary to systemic lupus erythematosus (SLE) who suffered from myocardial infarction and graft occlusion after coronary artery bypass surgery. Our patient illustrates the impact of accelerated atherosclerosis in patients with SLE and APS and the importance of early institution of antithrombotic therapies. In this article, the treatment of APS is summarized. Although the main stay of treatment is anticoagulation, there is emerging evidence to support rituximab as an option for “refractory” cases of APS.

Publisher

Walter de Gruyter GmbH

Subject

Earth-Surface Processes

Link

https://www.sciendo.com/pdf/10.2478/hkbrd-2018-0004

Reference39 articles.

1. Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E et al.; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015 Jun;74(6):1011–8.

2. Mok CC, Chan PT, Ho LY, Yu KL, To CH. Prevalence of the antiphospholipid syndrome and its effect on survival in 679 Chinese patients with systemic lupus erythematosus: a cohort study. Medicine (Baltimore). 2013 Jul;92(4):217–22.

3. Bundhun PK, Boodhoo KD, Long MY, Chen MH. Impact of antiphospholipid syndrome and/or systemic lupus erythematosus on the long-term adverse cardiovascular outcomes in patients after percutaneous coronary intervention: A systematic review and meta-analysis. Medicine (Baltimore). 2016 Mar;95(12):e3200.

4. Mineo C. Inhibition of nitric oxide and antiphospholipid antibody-mediated thrombosis. Curr Rheumatol Rep. 2013 May;15(5):324.

5. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987 Jun;327(6122):524–6.